Last reviewed · How we verify
Regadenoson; Optison
Regadenoson is a selective adenosine A2A receptor agonist.
Regadenoson is a selective adenosine A2A receptor agonist. Used for Nuclear stress test for coronary artery disease.
At a glance
| Generic name | Regadenoson; Optison |
|---|---|
| Also known as | Lexiscan is the brand name for regadenoson. |
| Sponsor | University of Nebraska |
| Drug class | adenosine receptor agonist |
| Target | A2A receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Regadenoson works by activating the adenosine A2A receptor, which increases coronary blood flow and myocardial perfusion. This results in increased oxygen delivery to the heart muscle, allowing for more accurate assessment of myocardial perfusion during stress testing.
Approved indications
- Nuclear stress test for coronary artery disease
Common side effects
- Headache
- Nausea
- Dizziness
- Flushing
- Vomiting
- Chest pain
- Shortness of breath
- Rapid heartbeat
- Abnormal ECG
- Hypotension
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Regadenoson; Optison CI brief — competitive landscape report
- Regadenoson; Optison updates RSS · CI watch RSS
- University of Nebraska portfolio CI